TNFRSF17 and Miyoshi myopathy: Indeed, a number of BCMA-targeting immunotherapies, including anti-BCMA antibody-drug conjugate [65,66,67,68], anti-BCMA bi-specific T cell engager (BiTE) [69,70], and BCMA-targeting chimeric antigen receptor T cells [71,72,73,74,75,76], have been developed and are at different stages of preclinical and clinical development for the treatment of resistant/relapsed MM and they have yielded promising results.